-+ 0.00%
-+ 0.00%
-+ 0.00%

CMG Pharmaceutical Faces Delisting Risk Over Minimum Share Price Requirement

PUBT·11/06/2026 08:20:26
Listen to the news
CMG Pharmaceutical Faces Delisting Risk Over Minimum Share Price Requirement
  • CMG Pharmaceutical faces delisting risk under Kosdaq rules; its common shares were designated for supervision on Aug. 13, 2026.
  • The designation followed 30 consecutive trading days with closing prices below KRW 1,000.
  • Delisting rules require closes of at least KRW 1,000 for 45 consecutive trading days within 90 trading days of designation.
  • As of Nov. 6, 2026, 41 trading days had elapsed, with shares meeting the price threshold for nine consecutive trading days.
  • A close below KRW 1,000 from the 46th trading day following designation could trigger delisting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CMG Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106900865), on November 06, 2026, and is solely responsible for the information contained therein.